Growth Hormone, 150 Minutes

Also known as: GH 150

Clinical Use

Use

For pediatric patients, very low peak growth hormone concentrations on stimulation testing are consistent with severe growth hormone deficiency (GHD). Thresholds distinguishing normal from partial GHD have not been well established, and an inadequate response to two different provocative tests is required for the diagnosis of GHD. In adults, expected peak growth hormone concentrations depend on the stimulation test performed, as described in Endocrine Society guidelines for the evaluation and treatment of adults with GHD. For suppression testing, healthy subjects have growth hormone concentrations of less than 1 ng/mL within two hours of ingestion of a 75 or 100 gram glucose dose, while patients with acromegaly fail to show normal suppression.

Special Instructions

Not provided.

Limitations

Thresholds distinguishing normal from partial growth hormone deficiency have not been well established. For an accurate diagnosis of growth hormone deficiency, an inadequate response to two different provocative tests is required. In suppression testing, failure to achieve normal suppression indicates acromegaly.

Test Details

FDA Approved

New York Approved

Methodology

Immunoassay (CLIA)

Biomarkers

Growth Hormone

Protein

GH concentration

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Result Codes

27369-8 - GH 2.5h p chal SerPl-mCnc

Result Turnaround Time

1-2 days

Specimen

Plasma

Volume

1 mL per timed specimen

Minimum Volume

0.4 mL per timed specimen

Container

Plasma Separator Tube (PST)

Collection Instructions

Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer to ARUP Standard Transport Tubes.